Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Intraocular Lymphoma × ibrutinib × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 42 Lymphoma, Mantle-Cell 20 Waldenstrom Macroglobulinemia 12 Lymphoma, Follicular 10 Lymphoma, Non-Hodgkin 9 Lymphoma, B-Cell 9 Leukemia 9 Lymphoma, Large B-Cell, Diffuse 8 Recurrence 6 Lymphoma, B-Cell, Marginal Zone 6 Lymphoma 5 Neoplasms 3 Leukemia, Lymphoid 3 Leukemia, B-Cell 3 Hodgkin Disease 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Multiple Myeloma 2 Leukemia, Myeloid, Acute 2 Leukemia, Hairy Cell 2 Chromosome 17 deletion 2 Burkitt Lymphoma 2 Bronchiolitis Obliterans Syndrome 2 Squamous Cell Carcinoma of Head and Neck 1 Smoldering Multiple Myeloma 1 Prostatic Neoplasms 1 Neoplasms, Plasma Cell 1 Neoplasm, Residual 1 Myeloproliferative Disorders 1 Melanoma 1 Mastocytosis, Systemic 1

Interventions

Rituximab 8 Cyclophosphamide 7 Peripheral Blood Stem Cell Transplantation 6 Methotrexate 6 fludarabine phosphate 5 Dexamethasone 5 Whole-Body Irradiation 4 Tacrolimus 4 Mycophenolic Acid 4 Cytarabine 4 Cyclosporine 4 Radiotherapy 3 Filgrastim 3 pegfilgrastim 2 etoposide phosphate 2 Transplantation 2 Lenalidomide 2 Granulocyte Colony-Stimulating Factor 2 Etoposide 2 Carboplatin 2 Calcium Dobesilate 2 Busulfan 2 Antilymphocyte Serum 2 zanubrutinib 1 sodium thiosulfate 1 sargramostim 1 oblimersen 1 merphos 1 ibrutinib 1 Vorinostat 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02542514 2022-04-14

iLOC

The Lymphoma Academic Research Organisation

Phase 2 Completed

Intraocular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡